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Poly-arginine R18 and R18D (D-enantiomer)
peptides reduce infarct volume and
improves behavioural outcomes following
perinatal hypoxic-ischaemic
encephalopathy in the P7 rat
Adam B. Edwards1,2,3, Jane L. Cross1,3,4, Ryan S. Anderton1,2,4, Neville W. Knuckey1,3,4 and Bruno P. Meloni1,3,4*

Abstract
We examined the neuroprotective efficacy of the poly-arginine peptide R18 and its D-enantiomer R18D in a
perinatal hypoxic-ischaemic (HI) model in P7 Sprague-Dawley rats. R18 and R18D peptides were administered
intraperitoneally at doses of 30, 100, 300 or 1000 nmol/kg immediately after HI (8% O2/92%N2 for 2.5 h). The
previously characterised neuroprotective JNKI-1-TATD peptide at a dose of 1000 nmol/kg was used as a control. Infarct
volume and behavioural outcomes were measured 48 h after HI. For the R18 and R18D doses examined, total infarct
volume was reduced by 25.93% to 43.80% (P = 0.038 to < 0.001). By comparison, the JNKI-1-TATD reduced lesion volume
by 25.27% (P = 0.073). Moreover, R18 and R18D treatment resulted in significant improvements in behavioural outcomes,
while with JNKI-1-TATD there was a trend towards improvement. As an insight into the likely mechanism underlying the
effects of R18, R18D and JNKI-1-TATD, the peptides were added to cortical neuronal cultures exposed to glutamic acid
excitotoxicity, resulting in up to 89, 100 and 71% neuroprotection, respectively, and a dose dependent
inhibition of neuronal calcium influx. The study further confirms the neuroprotective properties of polyarginine peptides, and suggests a potential therapeutic role for R18 and R18D in the treatment of HIE.
Keywords: Hypoxic-ischaemic encephalopathy, Hypoxia-ischaemia, Neuroprotection, Poly-arginine peptides,
R18, Cationic arginine-rich peptides (CARPs)

Introduction
In the human neonate, hypoxic-ischaemic encephalopathy (HIE) remains the leading cause of neonatal mortality and morbidity, with a reported incidence of 1–3 per
1000 live term births [1], [2]. Neurological sequelae associated with HIE include cerebral palsy, epilepsy, mental
retardation and learning disabilities [3]. Clinically, treatment to reduce brain injury for HIE is extremely limited,
consisting of moderate hypothermia (32–34 °C), maintained for up to 72 h. While hypothermia appears to be
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well tolerated, its safety has only been assessed in fullterm infants (37–40 weeks gestation), hence no
treatments are available for preterm neonates with HIE
born before 37 weeks gestation. In addition, while
hypothermia has been shown to improve outcomes in
clinical trials, 31–55% of infants do not benefit from the
therapy and suffer severe neurological sequelae [4]. Furthermore, hypothermia can only be used in hospital settings that have the necessary equipment and trained
staff to induce and monitor hypothermia following HIE,
and thus is not available in non-tertiary hospitals or hospitals located in remote locations and in many developing countries.
Due to the need for additional neuroprotective strategies for HIE, research has focused on the development
of a pharmacological neuroprotective agent that can be
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administered alone and/or in combination with current
hypothermia treatment to improve neonatal outcomes in
HIE. An added advantage of a pharmacological neuroprotective agent is the possibility it can be used in remote locations, is effective in preterm infants, and/or
can improve neuroprotective outcomes for hypothermia.
We and others have recently demonstrated that cationic
arginine-rich and poly-arginine peptides (hereafter referred to as CARPs) have potent neuroprotective properties in in vitro excitotoxicity neuronal injury models [5–
13], as well as in animal stroke models [10, 11, 14–16].
In particular, we have demonstrated that the polyarginine peptide, R18, is highly neuroprotective in permanent and transient middle cerebral artery occlusion
(MCAO) stroke models [11, 14–16].
While the exact mechanisms of the neuroprotective effects are still being explored, we and others have demonstrated that CARPs, including “putative” neuroprotective
peptides fused to cationic arginine-rich cell penetrating
peptides (i.e. TAT or R9; e.g. JNKI-1-TATD, TATNR2B9c/NA-1, TAT-CBD3/R9-CBD3-A6K and TAT3.2-III-IV) have the ability to mitigate excitotoxic or potassium evoked neuronal intracellular calcium influx [7,
8, 17–19], and in doing so, likely suppress damaging
down-stream signaling and cell death pathways. Beyond
this, we have demonstrated that the poly-arginine R12
and TAT-NR2B9c/NA-1 peptides reduce neuronal cell
surface expression of the glutamate receptor subunit
NR2B [20]. The ability of CARPs to reduce neuronal cell
surface levels of NR2B (due to internalization during
endocytic uptake) is at least one mechanism whereby
the peptides reduce the damaging effects of glutamateinduced calcium influx and excitotoxicity. Additionally,
other “putative” neuroprotective peptides bound to TAT
or R9 have been shown to reduce neuronal surface expression or activity of NMDA receptors [5, 21–23], as
well as voltage gated calcium channels CaV2.2 [21, 24,
25] and CaV3.3 [18], and the sodium calcium exchanger
3 (NCX3) [21]. Given their effects on different receptors,
presently, it cannot be ruled out that CARPs, due to
their cationic charge, are also antagonizing ion channel
receptor function directly and/or affecting calcium ion
influx via an electrostatic mechanism [7, 9].
In addition to CARPs reducing the effects of excitotoxicity, based on other properties of this class of peptide, they may exert more pleiotropic neuroprotective
effects by targeting mitochondria and maintaining mitochondrial integrity [6, 26–32], thereby reducing reactive
oxygen species (ROS) production and release of pro-cell
death proteins such as cytochrome-c. Furthermore,
CARPs have the capacity to inhibit proteolytic enzymes
including the proteasome [33, 34], as well as proprotein
convertases [35–37] that activate matrix metalloproteinases (MMPs) [38]. Inhibition of the proteasome is
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known to be beneficial following cerebral ischaemia [39,
40], a mechanism that could be mediated by increased
activity of hypoxia-inducible factor 1-α (HIF1α) and decreased activity of nuclear factor κ-light-chain-enhancer
of B cells (NFκB). Similarly, due to the damaging effects
of MMPs on the neurovascular unit and blood brain barrier, any down-regulation of their proteolytic activity is
likely to be beneficial following brain HI. In addition,
there is also evidence that CARPs can activate prosurvival signaling pathways [17, 41] and modulate immune responses [42–44], as well as act as anti-oxidant
molecules in their own right due to their guanidino
group containing arginine residues [32, 45–49].
Since HIE and stroke are thought to share many
pathophysiological processes (e.g. excitotoxicity and oxidative stress) it is likely that R18 will also be effective in
reducing HI brain injury. To this end, several CARPs, including “putative” neuroprotective peptides fused to
TAT such as JNKI-1-TATD [50], P5-TAT [51], TATNDB [52], TAT-mGluR1 [53], TAT-NR2B9c/NA-1 [53],
IDR-1018 [54], and COG133 [55], have demonstrated efficacy in perinatal HI models. Importantly, CARPs like
the TAT peptide also have cell penetrating properties
and can cross the blood brain barrier and enter the brain
[56–58].
Therefore, given the demonstrated efficacy of the R18
poly-arginine peptide in a number of experimental
stroke studies [11, 14–16], the present study examined
the neuroprotective efficacy and dose responsiveness of
R18, as well as its D-amino acid enantiomer (R18D) in a
perinatal HI model in the P7 Sprague-Dawley rat, and
their effects on neuronal calcium influx in an in vitro
glutamic acid excitotoxicity model. In addition, as a control, the study also examined the effects of the cationic
arginine-rich JNKI-1-TATD peptide, which has previously been shown to be neuroprotective in various rodent brain injury models, including perinatal HI [50, 59].

Methods
Animal ethics and study design

All experimental procedures in this study adhered to the
guidelines approved and specified by the Animal Ethics
Committee of the University of Western Australia (RA/
3/100/1329), in accordance with the Policies and Guidelines of the National Health and Medical Research
Council, Australia. Treatments were randomised and all
procedures (e.g. peptide administration, behavioural testing and infarct volume analysis) were performed while
being blinded to treatments.
Peptides used in the study

Peptides used in the study are shown in Table 1. R18,
R18D and JNKI-1-TATD used were synthesised by
Mimotopes (Melbourne, Australia). Peptides were purified
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Table 1 Peptides used in study
Peptide

Sequencea

Arginine/AA residues

% Arginine
residues

Net charge

R18

H-RRRRRRRRRRRRRRRRRR-OH

18/18

100

+ 18

R18D

H-rrrrrrrrrrrrrrrrrr-OH

18/18

100

+ 18

JNKD

H-tdqsrpvqpflnlttprkprpp-rrrqrrkkrg-NH2

9/32

28

+ 12

a
At the N-terminus, H indicates free amine. At the C-terminus, OH indicates free acid, and NH2 indicates amide. AA = amino acids. Lowercase single letter code
indicates D-isoform of the amino acid. JNKD = JNKI-1-TATD

using high performance liquid chromatography to at least
98% purity, and were subject to peptide hydrolysis and
amino acid liquid chromatography analysis to obtain a
precise measure of peptide content.
For the in vitro and animal studies, peptides were prepared as a 500 μM stock solution in water for irrigation
(Baxter, Australia), and in 0.9% sodium chloride for injection (Pfizer, Australia), respectively. Reconstituted
peptides were stored at − 20 °C until use.
Surgical procedure for modified Rice-Vannucci model

We used a modified Rice-Vannucci HI model. This involved occluding the right common, as well as the right
external carotid artery, a procedure that we have previously demonstrated to lead to the generation of a highly
reliable infarct [60]. Briefly, unsexed, Sprague-Dawley P7
rat pups (Animal Resource Centre, Murdoch, Australia;
P0 = day of birth) with a body weight of 13–16 g were
used. Litters were culled to a maximum of 12 pups per
litter to facilitate uniform growth without littermate
competition. Rat pups were anaesthetised using isoflurane (5% induction, 1–2% maintenance) in 100% oxygen,
while on a heating pad (37 °C). Through a 1 cm mid-line
ventral incision, the right common, internal and external
carotid arteries were exposed and isolated from the
vagus nerve, venous circulation and carotid body. The
right common carotid and external carotid arteries were
permanently ligated using 6–0 silk sutures. The wound
was closed using Vetbond (3M, Maplewood, USA) and
the animals were recovered on 100% oxygen for 5 min
on a heating pad. The duration of anaesthesia from induction to beginning of recovery was between 5 and
8 min. Animals were provided with analgaesia (pethidine, 5 mg/kg; intraperitoneally) immediately before cessation of anaesthesia. Sham-operated animals underwent
the same operative procedure, except the exposed carotid arteries were not ligated.
Rat pups were returned to their dam for 1 h before the
commencement of hypoxia which consisted of placing 4
to 6 pups in an airtight container (approximate volume:
4 L) and exposing them to humidified and warmed hypoxic gas (8% O2/92% N2; 3 L/min) for 2.5 h. The container was placed inside an incubator with an ambient
air temperature of 35 °C, ensuring a body temperature
of 36–37 °C, which was periodically monitored using an

infrared thermometer. Following hypoxia, animals were
placed on a heating pad for 5 min in a normoxic environment before being placed back with the dam. Shamoperated animals remained with the dam at all times.
Peptide administration

Immediately after hypoxia, treatments were administered
intraperitoneally (50 μl bolus) and consisted of either the
vehicle (saline; 0.9% sodium chloride), or R18 or R18D
at four different doses (30, 100, 300 or 1000 nmol/kg) or
JNKI-1-TATD at a single dose (1000 nmol/kg).
Animals used and sample size

One hundred and thirty-three Sprague-Dawley P7 pups
housed under controlled conditions on a 12-h light-dark
cycle underwent surgery for HI or the sham procedure
(i.e. anesthesia, neck incision, wound closure and analgesia). Twenty-seven animals were excluded from the
study; a list of animal exclusions is provided in Table 2.
The saline treatment group consisted of 19 animals and
the sham group 6 animals. All other treatment groups
consisted of between 7 and 11 animals (see Fig. 1a and
Table 3). Additional vehicle treated animals were included in the study to ensure that each batch of animals
subjected to HI contained a vehicle control and to increase the statistical power of the study.
Infarct volume assessment

Forty-eight hours after HI, animals were euthanised by
pentobarbital overdose (50 mg/kg; intraperitoneally). Infarct volume was determined by preparing 2 mm thick
coronal brain slices, and incubating in 3% 2,3,5-triphenyltetrazolium chloride (TTC; Sigma Aldrich, St. Louis,
USA) at 37 °C for 20 min, followed by fixation in 4% formalin at room temperature overnight. Digital images of
coronal slices were acquired using a colour scanner and
analysed, using ImageJ software (3rd edition, NIH, Bethesda, USA). Total infarct volume was determined by
measuring areas of infarcted tissue on both sides of the
2 mm slices. Infarct volume measurements were corrected for a degree of hemisphere volume changes [60].
Final infarct data is expressed as percentage infarct volume compared to whole brain (minus cerebellum). For
analysis of infarct volumes in male and female animals,
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Table 2 Animals excluded in the study
Exclusion rationale
No detectable infarct

Number of exclusions

Peptide

Dose

3

Saline

–

1

R18

300

3

R18

100

2

R18

300

1

R18

1000

2

R18D

30

1

R18D

300

1

R18D

1000

Total number of exclusions
15

1

JNKD

1000

Hyperthermiaa

1

R18

1000

1

Failure to complete behavioural
assessment

3

–

–

3

Surgical haemorrhageb

5

–

–

5

3

–

–

3

c

Premature death

All peptide doses are in nmol/kg. aHyperthermia is a recorded body temperature > 37.5. bSurgical haemorrhage is defined as any animal which had an abnormal
bleed (arterial rupture) during the surgical parameter. cPremature deaths occurred during hypoxia. JNKD = JNKI-1-TATD

due to low numbers of each gender per group, data for
the different doses of R18 and R18D were combined.

Behavioural assessment

To determine if the development of cerebral infarct was
associated with reduced sensorimotor outcomes, three
neurological tests (righting reflex, negative geotactic response and wire-hang) were performed at 48 h after HI,
as previously reported [60]. Briefly, for three consecutive
days before surgery (P4 to P6 inclusive), pups were accustomed to behavioural assessments with a target inclusion range of ≤2 s for the righting reflex and ≤30 s for
the negative geotactic response. Any animal that did not
record responses within these parameters at P7 (day of
surgery) were excluded from the experiment. All of these
reflexes are highly reproducible throughout the murine
pre-weaning period (< P30) and are strain- and genderindependent [61]. Each animal was given three attempts
to complete each sensorimotor task, with 5 min between
each attempt. Testing of all reflexes was performed on a
board covered with a tightly-stretched close knit-fabric,
to ensure adequate friction.
The righting reflex involved placing pups in a supine
position, and measuring the time required to rotate to
the prone position. The negative geotactic response involved placing pups facing down-slope, on a 45° angled
surface, and measuring the time required for the animal
to turn 150° upslope. Wire-hang test was performed by
suspending pups by their forelimbs on a 2 mm diameter
steel wire suspended 20 cm above a foam surface, and
recording the time taken for the animal to fall to the
foam surface.

Cortical neuronal cultures

Establishment of rat primary cortical neuronal cultures
was performed as previously described [8, 10]. Briefly,
cortical tissue was obtained directly from E18-day old
embryos. Dissociated neurons were seeded into 96-wellsized glass wells (7 mm diameter, Grace, Melbourne,
Australia), 96-well plastic plates (Nunc, Thermo Fisher
Scientific, Melbourne, Australia) in Neurobasal/2% B27
supplement (Life Technologies, Melbourne, Australia)
and maintained in a CO2 incubator (5% CO2, 95% air
balance, 98% humidity) at 37 °C until use on day in vitro
10 to 14. Under these conditions, cultures routinely consist of > 97% neurons and 1–3% astrocytes.
Glutamic acid excitotoxicity

A dose response experiment was performed as previously described [8]. Briefly, peptides in a 50 μl volume in
Minimum Essential Medium (Life Technologies)/2% B27
supplement (MEM/B27) were added to culture wells for
10 min at 37 °C in the CO2 incubator before the
addition of 50 μl MEM/B27 containing glutamic acid (Lglutamic acid; Sigma-Aldrich: 200 μM; final concentration 100 μM). Following a 5 min incubation at 37 °C in
the CO2 incubator (note: peptide concentration reduced
by half during this step), media was replaced with
100 μL MEM/B27 and cultures wells were incubated for
a further 24 h at 37 °C in the CO2 incubator. Untreated
controls with or without glutamic acid treatment underwent the same incubation steps and media additions.
At different times after treatment (e.g. 0.5 to 4 h and
18–24 h), cultures were examined by light microscopy
for qualitative assessment of neuronal cell viability.
Neuronal viability was quantitatively measured by MTS
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a

b

c

Fig. 1 Percentage infarct volume; percentage infarct volume, representative images of coronal brain slices and percentage infarct volume in brain slices
for the different treatment groups as determined 48 h after HI. Treatments were administered intraperitoneally (saline or R18, R18D and JNKI-1-TATD;
doses in nmol/kg) immediately after hypoxia. a Percentage of infarct volume when compared to total brain volume. b Representative TTC coronal brain
slice 2, from saline and peptide treated animals. Minor adjustments to brightness and contrast has been made to improve digital images. c Infarct volume
analysis in 2 mm coronal brain slices (slices numbered 1–6 from rostral to caudal) from saline and peptide treated animals. Statistical significance is
expressed in the table. Values are mean ± SE; *P < 0.05, **P < 0.01 when compared to saline. JNKD = JNKI-1-TATD

(3-(4,5,dimethyliazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H–tetrazolium salt) assay
(Promega, Sydney, Australia). The MTS absorbance data
were converted to reflect proportional cell viability relative to both the untreated (no insult; 100% viability) and
treated (glutamic acid; 5% viability) controls. At least

four wells were used in assays, repeated a minimum of
three to four times independently.
Intracellular calcium kinetics

Intracellular calcium influx was monitored as previously
described [8]. Briefly, primary cortical neuronal cultures
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Table 3 Cerebral infarct. Percentage of total cerebral volume
Treatment

Dose

N

Mean of total infarct volume (%)

SE
(%)

Reduction in total infarct volume (%)

P

Saline

–

19

18.24

1.393

–

–

JNKD

1000

7

13.63

2.843

25.27

0.073

R18

30

10

11.34

1.401

37.82

0.002

100

10

11.93

1.924

34.59

0.004

300

8

11.78

1.921

35.42

0.007

1000

11

10.25

2.082

43.80

< 0.001

30

9

13.51

2.058

25.93

0.038

100

9

10.33

0.874

43.36

< 0.001

300

9

12.07

1.540

33.82

0.007

1000

8

11.83

0.957

35.14

0.007

R18D

N number of animals, SE standard error of mean, P calculated compared to saline vehicle control. All doses are in nmol/kg. Mean and SE expressed as percentage
of total cerebral volume. JNKD = JNKI-1-TATD. Percentage reduction is mean percentage reduction compared to saline. All values P < 0.05 are in bold

were loaded with the fluorescent calcium ion indicator
Fura-2 AM (5 μM; Sigma Aldrich) in 50 μL MEM/B27,
0.1% pluronic F-127 (Sigma Aldrich), for 20 min at 37 °
C in the CO2 incubator. Fura-2 AM solution was removed from wells, replaced with 50 μL MEM/B27 containing peptides (R18 and R18D; 0.2, 2 and 5 μM) or
NMDA and AMPA receptor blockers (MK801/CNQX;
5 μM/5 μM; Tocris Bioscience, Bristol, United Kingdom)
and incubated for 10 min at 37 °C in the CO2 incubator.
Control cultures received 50 μL of MEM/B27 only. After
the 10 min incubation period, media in wells was replaced with 50 μL of balanced salt solution (BSS: mM:
116 NaCl, 5.4 KCl, 1.8 CaCl2, 0.8 MgSO4, 1 NaH2PO4;
pH 7.2) and wells transferred to a spectrophotometer
(BMG Labtec, CLARIOstar, Mornington, Australia)
while maintaining temperature at 37 °C. Fifty microliters
of BSS containing glutamic acid (200 μM; 100 μM final
concentration) was added to wells, and every 5 s, starting 30 s before and for 90 s after glutamic acid addition,
spectrophotometer measurements (excitation: 355 nm/
emission 495 nm) were recorded. Experiments were performed in triplicate. Area under the curve (AUC) for calcium kinetics data was calculated by trapezoidal
approximation of the AUC using fluorescent kinetic data
obtained after the addition of glutamic acid to wells.
Statistical analysis

The number of animals used in each experiment was
justified by statistical power calculation based on a previous study [60]. Group sizes have been calculated based
on a predicted treatment effect of 40%, at a power level
of 80–90% and an alpha level of 0.05. Mean percentage
infarct volume, behavioural measurements weight gain
and neuronal viability data were analysed by analysis of
variance (ANOVA), followed by post-hoc Fisher’s PLSD
test, with P < 0.05 values considered statistically significant. All descriptive statistics are presented in Table 3

and Additional file 1: Table S1, Additional file 2: Table
S2 and Additional file 3: Table S3.

Results
Infarct volume measurements

Data on infarct volume and representative TTC stained
coronal brain slices are presented in Fig. 1a and b. When
compared to the saline vehicle control (hereafter referred to as saline), both R18 and R18D significantly reduced infarct volume at all doses examined (30, 100, 300
and 1000 nmol/kg) by between 25.27 and 43.80% (P =
0.045 and < 0.001, respectively; refer to Table 3 for descriptive statistics). By comparison, the JNKI-1-TATD
peptide (1000 nmol/kg) reduced infarct volume by
25.27% (P = 0.073). No single R18, R18D or JNKI-1TATD dose was significantly more effective than any
other dose. To assess infarct development within 2 mm
coronal slices, rostral to caudal topographic analysis of
infarcts revealed that R18, R18D and JNKI-1-TATD at
all doses significantly reduced brain injury in one or
more coronal slices 1 to 6 (Fig. 1c; refer to Additional
file 1: Table S1 for descriptive statistics).
Behavioural outcomes, weight gain and gender analysis

Data on behavioural outcomes and weight gain is presented in Fig. 2a–h and descriptive statistics presented
in Additional file 2: Table S2. All data is transformed to
demonstrate the percentage improvement from baseline
for each treatment group, 48 h following HI. The sham
procedure is taken as equivalent to 100% improvement
and saline control to 0% improvement. The results of
the righting reflex test demonstrated that R18 (30 and
1000 nmol/kg) and R18D (300 and 1000 nmol/kg) significantly improved the righting reflex time by between
53.95% and 79.88% (P = 0.008 and 0.007), respectively,
when compared to saline. In comparison, animals
treated with JNKI-1-TATD (1000 nmol/kg) showed no

Edwards et al. Molecular Brain (2018) 11:8
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a

b

c

d

e

f

g

h

Fig. 2 Behavioural measurements using righting reflex, negative geotactic response, wire-hang test and weight gain 48 h after HI. Treatments were administered intraperitoneally (saline, R18, R18D or JNKI-1-TATD; doses in nmol/kg). The sham procedure group was assessed 48 h following sham-surgery.
a R18 righting reflex percentage improvement from 0 to 48 h. b R18D righting reflex percentage improvement from 0 to 48 h. c R18 negative geotactic
response percentage improvement from 0 to 48 h. d R18D negative geotactic response percentage improvement from 0 to 48 h. e R18 wire-hang percentage improvement from 0 to 48 h. f R18D wire-hang percentage improvement from 0 to 48 h. g R18 weight percentage improvement from 0 to
48 h. h R18D weight percentage improvement from 0 to 48 h. Values are mean ± SE. *P < 0.05 when compared to saline. JNKD = JNKI-1-TATD

statistically significant improvement, although there was
a trend towards improvement (43.87%; P = 0.063).
Analysis of the negative geotactic response test revealed that R18 (1000 nmol/kg) and R18D (100 and

1000 nmol/kg) significantly improved the time taken for
animals to rotate 150° up the 45° slope when compared
to saline by between 54.44% and 69.17% (P = 0.049 and
0.036), respectively. All other doses improved the
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negative geotactic response time by between 10.40% and
59.87% (P = 0.738 and 0.057), respectively. In comparison, JNKI-1-TATD (1000 nmol/kg) resulted in no statistically significant improvement, although there was a
trend towards improvement (42.18%; P = 0.187).
For the wire-hang test, only R18 at a dose of
1000 nmol/kg resulted in a statistically significant improvement in the time animals held onto the wire, increasing hang-time by 64.29% (P = 0.033) when
compared to saline. All other doses improved the wire
hang time by between 0.59% and 37.26% (P = 0.997 and
0.227), respectively. By comparison, JNKI-1-TATD
(1000 nmol/kg) resulted in no statistically significant improvement in the wire-hang time (30.93%; P = 0.374).
Analysis of weight gain over 48 h revealed that R18
at a dose of 1000 nmol/kg was the only treatment to
significantly improve weight gain (44.59%; P = 0.009)
when compared to saline (see Additional file 3: Table
S3 for descriptive statistics), while all other doses of
R18 and R18D demonstrated an increase in weight by
between 16.83% and 34.49% (P = 0.327 and 0.065), respectively. In comparison, JNKI-1-TATD (1000 nmol/
kg) treated animals demonstrated a gain in weight
(1.94%; P = 0.935). The only dose to demonstrate a
loss of weight was R18D at 1000 nmol/kg (−10.01%;
P = 0.659).
Analysis of R18 and R18D neuroprotective efficacy in
male and female animals revealed a significant reduction
in total infarct volume in both sexes when compared to
male and female saline treated animals (Additional file 4:
Figure S1; note: for analysis the different doses of R18
and R18D were combined). While intra-group comparisons demonstrated no significant differences in total infarct volumes between male and female animals treated
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with R18, R18D or saline; there was a trend towards reduced infarcts in female animals treated with R18 and
R18D (Additional file 4: Figure S1).

In vitro neuroprotective efficacy and calcium kinetics
following glutamic acid excitotoxicity

To provide an insight into the potential mechanism
of action of R18 and R18D, in vitro neuroprotective
efficacy and excitotoxic neuronal calcium influx kinetics were assessed. In line with previous findings from
our laboratory R18 and JNKI-1-TATD [7, 10, 11], as
well as R18D displayed dose-dependent neuroprotection following excitotoxicity (Fig. 3). For example,
R18 and R18D increased neuronal survival from 5%
for the glutamic acid control to 89% and 83% and
96% and 100% at 1 μM and 2 μM, respectively (Fig.
3). By comparison, JNKI-1-TATD increased neuronal
survival to 23 and 71% at 1 μM and 2 μM, respectively. As we have previously observed, higher peptide
concentrations (i.e. 5 μM) can have a negative impact
on neuronal survival [8], this was particularly evident
for R18D, a fact which most likely reflects the higher
stability of D-isoform peptides in the closed neuronal
culture system [9].
Again, in line with our previous findings, R18 and
JNKI-1-TATD [7, 10, 11], as well as R18D, reduced glutamic acid induced neuronal intracellular calcium influx
in a dose dependent manner (Fig. 4). In addition, the
calcium influx data for R18, R18D and JNKI-1-TATD
correlated with their neuroprotective effectiveness following glutamic acid excitotoxicity, with JNKI-1-TATD
displaying the least neuronal intracellular calcium influx
inhibitory effects.

Fig. 3 Glutamic acid excitotoxicity model; R18, R18D and JNKI-1-TATD dose response study. Peptides present in neuronal cultures 10 min before
and during 5 min glutamic acid exposure. Neuronal viability measured 24 h after glutamic acid exposure. Concentration of peptide in μmol/L.
MTS data were expressed as percentage neuronal viability with no insult (100% viability) and glutamic acid control (5% viability). Values are mean ± SE;
n = 4; *P < 0.05 when compared to no glutamic acid control. Cont = no treatment control. Glut = glutamic acid control. JNKD = JNKI-1-TATD
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a

b

Fig. 4 Intracellular calcium assessment using Fura-2 AM after glutamic acid exposure in primary neuronal cultures. a Fluorescent Fura-2 AM tracers;
fluorescent intensity (FI) of neuronal cultures 30 s before and after the addition (arrow) of glutamic acid (100 μM final concentration). Peptides (1, 2 and
5 μM) or glutamate receptor blockers (MK801/CNQX; 5 μM/5 μM) were added to neuronal cultures for 10 min and removed (time = 0) before glutamic
acid addition (time = 30 s). Values are mean ± SE; n = 3. b Trapezoidal area under the curve (AUC) approximation of calcium kinetic tracers. AUC is
determined at 35 s (point after glutamic acid addition. Values are mean ± SE; n = 3; *P < 0.05 when compared to glutamic acid control. Cont = no
treatment control. Glut = glutamic acid control. Blkrs = glutamate receptor blockers (MK801/CNQX; 5 μM/5 μM). JNKD = JNKI-1-TATD

Discussion
The present study extends our previous findings examining the neuroprotective effectiveness of CARPs in in
vitro and animal stroke injury models [7–11, 13–16]. In
doing so, the data provides compelling evidence for the
neuroprotective action of poly-arginine peptides R18
and R18D, as well as the JNKI-1-TATD peptide, which is
also a CARP, in a modified Rice-Vannucci model of HIE.
The modified Rice-Vannucci model used in this study

leads to the generation of a more reproducible infarct,
accompanied with a greater severity of brain injury [60].
The original and modified Rice-Vannucci models are
likely to mimic the clinical development of a pattern of
brain injury, whereby white matter and cerebral cortex,
supplied by the middle cerebral and posterior cerebral
arteries, are affected following prolonged birth asphyxia
[62]. Importantly, the neuroprotective actions of R18
and R18D, as measured in terms of infarct volume, was
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associated with improved behavioural outcomes at a
number of the peptide doses with respect to the righting
reflex, negative geotactic response and wire-hang tests,
while JNKI-1-TATD only demonstrated trends towards
improvement in the righting reflex and negative geotactic response tests. In addition, unlike JNKI-1-TATD,
some doses of R18 and R18D improved weight gain following HI. This is another indicator for improved behavioural outcomes as it is likely to reflect the animals’
increased motor capacity to search and feed from the
dam, as well as potential reduced weight loss due to increases in respiratory demand, metabolic rate and cachexia [63]. Furthermore, treatment with R18 and R18D
was effective at reducing total infarct volume in both
male and female animals following HI.
It is noteworthy that, the R18 and R18D were highly
effective at reducing infarct volume at all doses examined without displaying a typical dose response effect.
The efficacy of both R18 and R18D over a wide dose
range (30–1000 nmol/kg) is highly significant, which ultimately could translate to the peptides being effective at
low doses when used clinically following HIE. The effectiveness of JNKI-1-TATD (also referred to as XG-102)
in a wide dose range with IP administration has also
been demonstrated previously following transient
MCAO in adult mice [64] and following permanent
MCAO in P14 rats [65].
In the present study, R18 and R18D appeared more effective than JNKI-1-TATD across all the in vivo (infarct
volume and behavioural outcomes) and in vitro (neuroprotection and neuronal intracellular calcium influx inhibition) outcomes examined. The lower efficacy of
JNKI-1-TATD may reflect its lower arginine content (R
= 9) and cationic charge (+ 12) compared to R18 and
R18D (R = 18, charge = + 18). On this point, our previous
studies have confirmed that CARP neuroprotective efficacy and neuronal excitotoxic influx inhibition increases
with increasing peptide arginine content and peptide
positive charge [8, 9]. It is also noteworthy that in the
present study, no obvious overall differences were uncovered between the R18 peptide and its R18D
enantiomer.
As mentioned above, the only currently available treatment known to improve neurological outcomes following HIE is moderate hypothermia (32–34 °C for 72 h).
As such there is an urgent need for the development of
an effective pharmacological neuroprotective agent that
can be readily administered following HIE and that is
compatible and synergistic with hypothermia. Therefore,
it will be important in future studies to assess whether
R18 or R18D treatment is compatible with hypothermia,
and whether the combined therapies have an additional
effect in reducing brain injury and improving behavioural outcomes. In addition, whilst a 48 h endpoint is
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commonly used in initial neuroprotective and pathophysiological investigations, it is important that the effectiveness of R18 and R18D at more extended timepoints should also be evaluated. We also recognise that
the IP route for peptide administration may not be
ideally suited to the clinical situation, and that an intravenous (IV) route would be preferable. Furthermore,
due to the potential differences in blood pharmacokinetics following IP or IV administration of R18 and R18D,
at present it is not known how the different delivery
routes would impact on the neuroprotective efficacy of
the peptides. To this end, further assessment of R18 and
R18D when administered by the IV route could be more
appropriately carried out in a large animal model of HI
(i.e. piglet or lamb).
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